This article was originally published in The Gray Sheet
Offers to acquire AccuMed International's AcCell 2000, 2001 and 3000 cytopathology systems used in the diagnosis of Pap smears and other cytology specimens. Ampersand also seeks to acquire "all intellectual properties" related to the technologies and AccuMed's contracted customer base, the privately held Chicago firm says. The offer "includes cash plus a royalty and a license back to AccuMed for certain technology owned by Ampersand that may be used on AccuMed's Savant system"
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.